Raman seminar at the Natural History Museum
3 November 2011 | By Renishaw
Raman spectroscopy came under the spotlight recently at the Natural History Museum in London...
List view / Grid view
3 November 2011 | By Renishaw
Raman spectroscopy came under the spotlight recently at the Natural History Museum in London...
2 November 2011 | By Eli Lilly and Company
John Lechleiter calls for balanced decision-making...
1 November 2011 | By College Hill
Sanofi is expected to take the top spot amongst the world’s pharmaceuticals manufacturers in 2012...
1 November 2011 | By Daiichi Sankyo
Daiichi Sankyo has established a new Japanese vaccine research unit to be located in its Kasai R&D Center...
Teva UK Limited has announced that Richard Daniell has been appointed as Managing Director, responsible for all Teva’s commercial activities in the UK.
1 November 2011 | By Abbott
FDA approval for the next-generation XIENCE PRIME™ Drug Eluting System...
31 October 2011 | By University of Strathclyde
A pioneering research institute to drive forward the search for new and better medicines to open...
28 October 2011 | By Pfizer
Pfizer Inc. has completed its acquisition of Icagen, Inc., through the merger of its wholly owned subsidiary, Eclipse Acquisition Corp., with and into Icagen...
28 October 2011 | By H. Lundbeck A/S
Lundbeck has appointed Jens Peter Balling and Iman Barilero as vice presidents in its research and development organisation...
27 October 2011 | By Mike Claybourn, Raman Product Manager, HORIBA Scientific, 16 rue du Canal, 91160 Longjumeau France
Raman spectroscopy, a technology that has a long pedigree of success in Pharmaceutical Development...
27 October 2011 | By Boehringer Ingelheim
Update across Europe on Pradaxa®...
26 October 2011 | By Biogen Idec
Positive top-line results announced...
26 October 2011 | By Bristol-Myers Squibb Company
Licensing agreement for Bristol-Myers Squibb to develop and commercialize a fixed-dose combination...
26 October 2011 | By GlaxoSmithKline
GSK has joined WIPO Re:Search...
26 October 2011 | By AstraZeneca
US FDA has extended the action date for dapagliflozin for the treatment of type 2 diabetes by three months...